

Article

The Use of Positron Emission Tomography in Soft Tissue Sarcoma Patients under Therapy with Trabectedin

Bernd Kasper ^{1,*}, Thomas Schmitt ¹, Patrick Wuchter ¹, Antonia Dimitrakopoulou-Strauss ², Anthony D. Ho ¹ and Gerlinde Egerer ¹

¹ Department of Internal Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, D-69120 Heidelberg, Germany; E-Mails: Thomas.Schmitt@med.uni-heidelberg.de (T.S.); Patrick.Wuchter@med.uni-heidelberg.de (P.W.); Anthony.Ho@med.uni-heidelberg.de (A.H.); Gerlinde.Egerer@med.uni-heidelberg.de (G.E.)

² Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany; E-Mail: ads@ads-lgs.de

* Author to whom correspondence should be addressed; E-Mail: mail@berndkasper.de; Tel.: +49-6221-56-8008; Fax: +49-6221-56-6824

Received: 23 June 2009; in revised form: 14 July 2009 / Accepted: 17 July 2009 /

Published: 17 July 2009

Abstract: *Background:* We used 2-deoxy-2-[¹⁸F] fluoro-D-glucose (FDG) positron emission tomography (PET) to evaluate the FDG uptake in patients with advanced and/or metastatic soft tissue sarcoma (STS) undergoing therapy with Ecteinascidin-743 (ET-743, Trabectedin, YondelisTM). *Patients and Methods:* The pilot study included nine patients with metastatic STS receiving a minimum of one cycle of treatment with trabectedin. Patients were examined using PET prior to onset of therapy and after completion of one or three cycles of trabectedin. Restaging according to Response Evaluation Criteria in Solid Tumours (RECIST) was performed in parallel using computed tomography (CT) and/or magnetic resonance imaging (MRI) and served for reference. *Results:* Clinical outcome of nine evaluable patients was as follows: one patient with partial remission (PR), three patients with stable disease (SD), and five patients with progressive disease (PD). A more than 40% decrease of the standardized uptake value (SUV) of sequential PET examination could be demonstrated for the responding patient (PR), whereas patients with SD or PD showed a stable SUV, but no increase in SUV. *Conclusion:* To our knowledge, this is the first small series of patients being treated with trabectedin and monitored using sequential PET imaging demonstrating SUV stabilization in nearly all monitored patients.

Keywords: fluorodeoxyglucose; positron emission tomography; RECIST, soft tissue sarcoma; trabectedin

1. Introduction

Soft tissue sarcomas (STS) are a heterogeneous group of connective tissue malignancies arising from tissue of mesenchymal origin. They constitute less than 1% of all adult malignancies. The five-year overall survival rate in patients with STS of all stages amounts to only 50–60% [1]; most patients die of metastatic disease, which becomes evident in 80% of the cases within two to three years after initial diagnosis [2]. Despite improvements in local tumour control rates, the treatment of patients with high risk STS remains challenging. For patients with no evidence of metastatic disease surgery is the primary treatment of choice. The high rate of distant disease recurrence suggests that undetectable metastatic disease is present in a significant percentage of patients with large, high grade STS at the time of surgery. Therefore an effective systemic treatment with chemotherapy is needed. Doxorubicin and ifosfamide are the most active single-agents in the therapy of STS with response rates above 20% [3]. So far, the benefit of neither adjuvant chemotherapy [4] nor neoadjuvant chemotherapy has yet been finally clarified [5].

Therefore, it is important to identify patients who are likely to benefit from chemotherapy or other molecular targeted agents. Morphologic imaging modalities like CT and MRI can be used for the assessment of tumour localization, size, and infiltration of the surrounding tissue as well as presence of satellite metastases. However, it has not been well established whether a significant change in the tumour size is a meaningful tool of outcome of patients with STS. Standard radiographic response has not correlated consistently with histological response or with disease-free or overall survival [6–7]. Other methods to identify patients who are likely to benefit from chemotherapy or other agents would be useful. Therefore, PET with ^{18}F -FDG has found increasing use in oncology, because it allows functional imaging of viable tumour tissue [8]. However, not all tumours are PET avid, despite being viable.

It was shown that FDG PET can visualize STS and detect local and distant recurrence of disease [9–10]. It was demonstrated that the SUV correlates well with the metabolic rate of FDG accumulation in tumour cells [11]. Hence, the SUV could function as an easily measurable surrogate of tumour viability during therapy. For other tumour entities, correlation between FDG accumulation after neoadjuvant chemotherapy and histological response as well as tumour response was shown, for example in breast cancer [12], oesophageal cancer [13], colorectal cancer [14], and gastrointestinal stromal tumours [15]. In a group of 46 patients with localized, intermediate/high grade, extremity STS, Schuetze et al. could demonstrate that changes of the SUV before and after neoadjuvant chemotherapy can be used to predict therapy outcome [16]. The multivariate analysis found a correlation between lack of response and increased risk of disease recurrence, metastases and death after appropriate local control of sarcoma. This study suggested that FDG PET can act as a non-invasive method in high risk extremity STS to predict patients who are less likely to benefit from doxorubicin-based chemotherapy [17].

Ecteinascidin-743 (ET-743, Trabectedin, YondelisTM) is a tetrahydroisoquinoline alkaloid isolated from the Caribbean marine tunicate, *Ecteinascadia turbinata*. ET-743 is a DNA guanine-specific minor groove binding agent that blocks the cell cycle in the late S and G phase. Five phase II trials in Europe and the United States revealed a response rate of 10% in pre-treated and 18% in untreated patients with response duration of about ten months and a progression-free survival of 24% at 6 months and 9% at 12 months [18–19]. In particular, anti-tumour activity has been demonstrated in leiomyosarcomas and liposarcomas. ET-743 seems to be especially active in the myxoid variant of liposarcomas associated with translocations of t(12;16)(q13;p11) or t(12;12)(q13;q12); among 15 retrospectively reviewed cases eight objective responses were found [20]. There is only one phase I study monitoring patients being treated with trabectedin with FDG PET. Although there were no objective responses to therapy, clear evidence of anti-tumour activity was observed in a patient with epithelioid mesothelioma as confirmed by PET [21].

The purpose of the present study, which is the first covering this topic, was to analyse and discuss semi-quantitative FDG PET measurements in STS patients treated with trabectedin.

2. Patients and Methods

Patients

The pilot study includes nine patients with STS. Patients' characteristics including gender, age, histologies and grading according to the Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system [22], tumour and metastatic sites as well as line of treatment are summarized in Table 1. All patients were referred to our outpatient service with a diagnosis of a STS confirmed by histology obtained from surgical specimens. Tumour specimens were classified according to the FNCLCC system. Patients were treated with trabectedin in the Department of Internal Medicine V, University of Heidelberg between September 2008 and June 2009. The research was carried out according to the principles set out in the Declaration of Helsinki in 1964 and all subsequent revisions.

Ecteinascidin-743

Nine patients with metastatic disease received trabectedin in a dose of 1.5 mg/m²/day 1 as a 24 hour continuous infusion, repetition day 22 for at least one cycle. Altogether, we performed 18 cycles of therapy; treatment was continued until disease progression. One patient received trabectedin in a reduced dose of 1.3 mg/m² because of liver metastases with elevated liver parameters. In spite of CTCAE grade I/II fatigue, nausea and neutropenia, no major (grade III and IV) toxicities occurred.

Imaging studies

Patients were examined using FDG PET prior to onset of therapy and after completion of one to three cycles of trabectedin. Conventional imaging of the same target lesion using CT and/or MRI was performed in parallel to determine the response according to RECIST criteria. This data served as reference to evaluate the response determined with FDG PET. Dynamic PET studies were performed

after intravenous injection of 300–370 MBq FDG for 60 min. A dedicated PET system (ECAT EXACT HR plus, Siemens, Erlangen, Germany) was used for patient studies as described before [23]. The last images (55–60 minutes post-injection) were used for semi-quantitative analysis. PET cross-sections were reconstructed with an image matrix of 256×256 using an iterative reconstruction program. Images were scatter- and attenuation-corrected. Volumes of interest (VOI) were placed over the lesion. To acquire information about the tumour viability, the hyper-metabolic areas of the tumours were evaluated and hypo-metabolic areas that correlate to necrotic tissue were excluded. The SUV in the tumour was calculated according to the following equation: $SUV = \text{tissue concentration (MBq/g)} / [\text{injected dose (MBq)}/\text{body weight (g)}]$. The SUV reflected the average SUV value provided by the quantification software in a VOI. This value is more robust than the maximum SUV (SUV_{\max}), because it is less influenced by the parameters used for the image reconstruction as well as by potential artefacts. The analysis of the PET images was performed together by two nuclear medicine physicians using the software package Pmod (PMod Technologies Ltd., Adliswil, Switzerland) [24].

Statistical analysis

Due to the small number of patients we performed a descriptive analysis of the data. Progression-free survival was defined as the time interval from the date of therapy induction until the tumour recurred or the patient died of sarcoma-related causes.

Table 1. Patients' characteristics (n = 9).

<i>Gender</i>	Female	6
	Male	3
<i>Age</i>	Median (years)	52 [range: 26–73]
<i>Histology</i>	Synovial sarcoma	2
	Leiomyosarcoma	7
<i>Grading</i>	II	2
	III	7
<i>Tumour site at initial diagnosis</i>	None	1
	Extremities	3
	Trunk	5
<i>Metastatic sites</i>	Lung	8
	Liver	3
	Lymph nodes	3
	Soft tissue	2
<i>Line of Treatment</i>	2 nd line	4
	3 rd line or more	5

3. Results and Discussion

Clinical response based on RECIST criteria

First CT and/or MRI scan was performed in all patients prior to onset of therapy with trabectedin. Restaging was performed using CT and/or MRI after one ($n = 2$) or three ($n = 4$) cycles of trabectedin. The remission status was evaluated according to RECIST criteria based on the tumour shrinkage in the CT and/or MRI scan. Clinical outcome according to RECIST criteria was as follows: one patient with PR, three patients with SD, and five patients with PD. The median progression-free survival from the date of therapy induction for all patients was 2.8 months [range: 0–7] with a median follow-up of 3.8 months [range: 1–7].

Clinical response based on PET imaging


The median average SUV prior to onset of targeted therapy with trabectedin was 7.6 [range: 1.2–19.3] in comparison to 5.8 [range: 1.4–20.1] after treatment. The median SUV_{max} was 14.1 [range: 4.5–28.7] prior to therapy with trabectedin in comparison to 16.1 [range: 6.1–32.4] following treatment. We compared the average SUV values with the clinical response data according to RECIST criteria using conventional MRI and/or CT. One patient achieving PR showed a significant decrease of the SUV ($6.7 > 3.5$, decrease of 48%) and the SUV_{max} ($13.5 > 6.1$, decrease of 54%) indicating tumour response to treatment; the patient further continued treatment with trabectedin. In the literature, a cut-off value of 40% reduction from baseline has been chosen to differentiate responders [25]. Three patients with SD after one ($n = 2$) or three ($n = 1$) cycles of trabectedin demonstrated no major change in SUV indicating tumour stabilization; all patients continued treatment with trabectedin. Two patients with PD under treatment with trabectedin also showed stabilization of the SUV; nevertheless, treatment with trabectedin was stopped due to RECIST criteria. Two patients received only one cycle of trabectedin and died within one month after start of therapy due to PD and therefore were not evaluable regarding sequential PET examinations. One patient received two cycles of trabectedin and showed documented PD; no PET follow-up examination was performed due to refusal of the patient. Hence, a significant decrease ($> 40\%$) of the SUV of the sequential PET examinations could be demonstrated for one responding patient (PR), whereas patients with SD or even PD showed stabilization of the SUV. There was no patient in this series demonstrating an increase of the SUV. The PET examinations seem to confirm what we know about the characteristics of trabectedin; it has a remarkable ability to slow the growth and stabilize the tumour, which is reflected by our results regarding SUV values. Moreover, we could show that sequential PET imaging with a second PET scan after treatment with trabectedin may be used to determine whether STS patients will benefit from therapy or not.

Example

In order to demonstrate that PET imaging may provide additional information compared to conventional MRI and/or CT, we describe a case from one of our patients (Figure 1): A 62 year old

female with a leiomyosarcoma, grade III, of the vena cava with lung and liver metastases. The FDG PET prior therapy with trabectedin showed an average SUV of 6.7 and a SUV_{max} of 13.5 (*upper left image*). After three cycles of treatment with trabectedin, the FDG PET demonstrated a decrease of the average SUV to 3.5 and of the SUV_{max} to 6.1 (*upper right image*) and a decrease of the FDG uptake in all other evaluable lesions. The corresponding conventional CT documented PR according to RECIST (*lower left and right images*). This case underlines the common finding that the structure of the tumour may change reflected by a decline of the average and the maximum SUV caused by a change of the vessel density, blood circulation or necrosis even though the tumour size itself remains rather stable.

Figure 1. Case of a 62 year old female with a leiomyosarcoma, grade III, of the vena cava with lung and liver metastases. FDG PET showed a decrease of the average SUV from 6.7 and of the SUV_{max} from 13.5 (*upper left image*) to 3.5 and 6.1 (*upper right image*), respectively, as well as a decline of the FDG uptake in all evaluable lesions (mSUV PET images, colour-scales are directly comparable (0–10 SUV)). As an example, the corresponding CT scan showed the reduction in size of one reference lesion in the lung demonstrating a PR according to RECIST criteria (*lower left and right images*). Additionally, liver metastases demonstrated a partial remission (not shown).



Discussion

There have been different implications for the use of PET in STS. It has been studied to predict the malignant potential and grade of tumours, to stage the malignant disease, to monitor tumour response to chemotherapy, to predict clinical benefit from chemotherapy, and to detect tumour recurrence after primary therapy [26]. However, most of the studies have analysed only a small number of patients and have used different imaging protocols and evaluation procedures. Therefore, comparison of the different studies and analysis seems to be difficult. Nevertheless, there is no doubt that FDG PET is useful in the clinical management of bone and soft tissue sarcoma patients [17].

During the last decade change in tumour size to cytotoxic treatment has been the parameter to predict the therapeutic benefit for the patients. However, changes in tumour size in soft tissue sarcomas measured with CT and/or MRI were not correlated consistently with patients' outcomes. Especially for gastrointestinal stromal tumours (GIST), this finding has already been well documented. A study of FDG PET in imatinib treated GIST showed that patients with normalization of tumour SUV within the first month of treatment have significantly longer time to progression of disease and better overall survival than those patients with increased FDG accumulation [27]. FDG PET appears to be more useful than CT/MRI imaging in GIST to predict response to therapy. Moreover, there is even doubt if RECIST criteria adequately describe the remission status to chemotherapy or to other targeted agents.

To our knowledge, the present paper describes the first small series of heavily pre-treated patients under therapy with trabectedin being monitored using sequential PET imaging. The purpose of the study was to describe certain PET characteristics of trabectedin and to identify patients who are likely to benefit from treatment. In our own study with high grade STS patients receiving neoadjuvant chemotherapy, we could demonstrate that FDG PET may be used as a tool to predict patients' therapy outcome while differentiating between responders and non-responders after a limited drug exposure [28]. There is only one phase I study using FDG PET to monitor patients receiving trabectedin. Although there were no objective responses in that study, clear evidence of anti-tumour activity was observed in one patient with epithelioid mesothelioma as confirmed by a 40% reduction in FDG uptake after two cycles [21]. In our population of heavily pre-treated patients, we demonstrated a more than 40% decline of the SUV in our sequential PET examination for one responding patient (PR), whereas all patients with SD or even PD showed stabilization of the SUV. There was no patient demonstrating a SUV increase. However, the present data could not add any additional information to conventional imaging methods using CT and/or MRI. PET scan should be most useful in patients with SD; however, there was no change in SUV in this group of patients. Of course, these limitations of the study could be due to the low number of evaluated patients or to the short follow-up time of the present data.

4. Conclusions

Taken together, FDG PET will certainly play an increasingly important prognostic and predictive role in the management of sarcomas. It could be used to assess the aggressiveness of the tumour in order to make early clinical decisions whether treatment is useful for the patient or not [28]. Our

present data suggest that the characteristics of trabectedin are reflected by PET examinations. Trabectedin shows a remarkable ability to slow the growth and stabilize the tumour indicated by stabilization or even decrease of the SUV values. Furthermore, PET imaging may be used in order to predict response to therapy early in the course of treatment for cytotoxic chemotherapy as well as targeted agents such as kinase inhibitors or trabectedin. However, more data have to be evaluated. FDG PET imaging may complement radiological tomography and histological grading, thus improving the assessment of STS and implying an influence on therapeutic decisions in the future.

References

1. Pisters, P. Staging and Prognosis. In *American Cancer Society Atlas of Clinical Oncology: Soft Tissue Sarcomas*; Pollock, R.E., Ed.; BC Decker, Inc.: Hamilton, ON, Canada, 2002; pp. 80–88.
2. Standard-Options-Recommendations. In *Sarcome des Tissues Mous et Ostéosarcomes*; Arnette Blackwell: Paris, France, 1995; Vol. 1. pp. 1–113.
3. Verweij, J.; Mouridsen, H.T.; Nielsen, O.S.; Woll, P.J.; Somers, R.; van Oosterom, A.T.; van Glabbeke, M.; Tursz, T. The present state of the art in chemotherapy for soft tissue sarcomas in adults: The EORTC point of view. *Crit. Rev. Oncol. Hematol.* **1995**, *20*, 193–201.
4. Frustaci, S.; de Paoli, A.; Bidoli, E. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. *Oncology* **2003**, *65*, 80–84.
5. Grobmyer, S.R.; Maki, R.G.; Demetri, G.D.; Mazumdar, M.; Riedel, E.; Brennan, M.F.; Singer, S. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. *Ann. Oncol.* **2004**, *15*, 1667–1672.
6. Pisters, P.W.; Patel, S.R.; Varma, D.G.; Cheng, S.C.; Chen, N.P.; Nguyen, H.T.; Feig, B.W.; Pollack, A.; Pollock, R.E.; Benjamin, R.S. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. *J. Clin. Oncol.* **1997**, *15*, 3481–3487.
7. Wendtner, C.M.; Abdel-Rahman, S.; Krych, M.; Baumert, J.; Lindner, L.H.; Baur, A.; Hiddemann, W.; Issels, R.D. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. *J. Clin. Oncol.* **2002**, *20*, 3156–3164.
8. Strauss, L.G.; Conti, P.S. The applications of PET in clinical oncology. *J. Nucl. Med.* **1991**, *32*, 623–648.
9. Schulte, M.; Brecht-Krauss, D.; Heymer, B.; Guhlmann, A.; Hartwig, G.; Sarkar, M.R.; Diederichs, C.G.; Schultheiss, M.; Kotzerke, J.; Reske, S.N. Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is a non-invasive determination of biological activity possible? *Eur. J. Nucl. Med.* **1999**, *26*, 599–605.
10. Schwarzbach, M.; Dimitrakopoulou-Strauss, A.; Willeke, F.; Hinz, U.; Strauss, L.G.; Zhang, Y.M.; Mechtersheimer, G.; Attigah, N.; Lehnert, T.; Herfarth, C. Clinical value of [¹⁸F]fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. *Ann. Surg.* **2000**, *231*, 380–386.

11. Eary, J.F.; Mankoff, D.A. Tumor metabolic rates in sarcoma using FDG PET. *J. Nucl. Med.* **1998**, *39*, 250–254.
12. Schelling, M.; Avril, N.; Nahrig, J.; Kuhn, W.; Romer, W.; Sattler, D.; Werner, M.; Dose, J.; Janicke, F.; Graeff, H.; Schwaiger, M. Positron emission tomography using [¹⁸F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. *J. Clin. Oncol.* **2000**, *18*, 1689–1695.
13. Gretschel, S.; Moesta, K.T.; Hünerbein, M.; Lange, T.; Gebauer, B.; Stroszczinsk, C.; Bembenek, A.; Schlag, P.M. New concepts of staging in gastrointestinal tumors as a basis of diagnosis and multimodal therapy. *Onkologie* **2004**, *27*, 23–30.
14. Dimitrakopoulou-Strauss, A.; Strauss, L.G.; Burger, C.; Ruhl, A.; Irngartinger, G.; Stremmel, W.; Rudi, J. Prognostic aspects of ¹⁸F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy. *J. Nucl. Med.* **2004**, *45*, 1480–1487.
15. Stroobants, S.; Goeminne, J.; Seegers, M.; Dimitrijevic, S.; Dupont, P.; Nuyts, J.; Martens, M.; van den Borne, B.; Cole, P.; Sciot, R.; Dumez, H.; Silberman, S.; Mortelmans, L.; van Oosterom, A. ¹⁸F-FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). *Eur. J. Cancer.* **2003**, *39*, 2012–2020.
16. Schuetze, S.M.; Rubin, B.P.; Vernon, C.; Hawkins, D.S.; Bruckner, J.D.; Conrad, E.U., 3rd; Eary, J.F. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. *Cancer* **2005**, *103*, 339–348.
17. Schuetze, S.M. Utility of positron emission tomography in sarcomas. *Curr. Opin. Oncol.* **2006**, *18*, 369–373.
18. Verweij, J. Ecteinascidin-743 (ET-743): Early test or effective treatment in soft tissue sarcomas? *J. Clin. Oncol.* **2005**, *24*, 5420–5423.
19. Fayette, J.; Coquard, I.R.; Alberti, L.; Ranchère, D.; Boyle, H.; Blay, J.Y. ET-743: A novel agent with activity in soft-tissue sarcomas. *Curr. Opin. Oncol.* **2006**, *18*, 347–353.
20. Grosso, F.; Forni, C.; Frapolli, R.; Greco, A.; Gronchi, A.; Jimeno, J.; Mantovani, R.; D'Incalci, M.; Pilotti, S.; Casali, P.G. Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. *Proc. Am. Soc. Clin. Oncol.* **2007**, *25*, 18S (abstract 10000).
21. Ryan, D.P.; Supko, J.G.; Eder, J.P.; Seiden, M.V.; Demetri, G.; Lynch, T.J.; Fischman, A.J.; Davis, J.; Jimeno, J.; Clark, J.W. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. *Clin. Cancer Res.* **2001**, *7*, 231–242.
22. Trojani, M.; Contesso, G.; Coindre, J.M.; Rouesse, J.; Bui, N.B.; de Mascarel, A.; Goussot, J.F.; David, M.; Bonichon, F.; Lagarde, C. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. *Int. J. Cancer.* **1984**, *33*, 37–42.
23. Schwarzbach, M.H.; Hinz, U.; Dimitrakopoulou-Strauss, A.; Willeke, F.; Cardona, S.; Mechtersheimer, G.; Lehnert, T.; Strauss, L.G.; Herfarth, C.; Buchler, M.W. Prognostic significance of preoperative [¹⁸F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. *Ann. Surg.* **2005**, *241*, 286–294.

24. Burger, C.; Buck, A. Requirements and implementation of a flexible kinetic modelling tool. *J. Nucl. Med.* **1997**, *38*, 1818–1823.
25. Cheng, E.Y.; Froelich, J.W.; Manivel, J.C.; Weigel, B.J.; Skubitz, K.M. Correlation of FDG-PET with histologic response after neoadjuvant chemotherapy for soft tissue sarcomas. *Proc. Am. Soc. Clin. Oncol.* **2009**, *25*, 18S (abstract 10583).
26. Dimitrakopoulou-Strauss, A.; Strauss, L.G.; Schwarzbach, M.; Burger, C.; Heichel, T.; Willeke, F.; Mechtersheimer, G.; Lehnert, T. Dynamic PET ¹⁸F-FDG studies in patients with primary and recurrent soft tissue sarcomas: impact on diagnosis and correlation with grading. *J. Nucl. Med.* **2001**, *42*, 713–720.
27. Jager, P.L.; Gietema, J.A.; van der Graaf, W.T. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. *Nucl. Med. Commun.* **2004**, *25*, 433–438.
28. Kasper, B.; Dietrich, S.; Dimitrakopoulou-Strauss, A.; Strauss, L.G.; Haberkorn, U.; Ho, A.D.; Egerer, G. Early prediction of therapy outcome in patients with high risk soft tissue sarcoma using positron emission tomography. *Onkologie* **2008**, *31*, 107–112.

© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).